Clinical trials: Lung Tumors
Brain Metastases, Adult
Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Brain metastases (BM) represents a devastating clinical reality, carrying an estimated survival time of less than one year. Number of reasons, including complicated tumor biology and difficulties in modeling metastatic cancer in…
- Trial name
- NCT04785521
- Testing
- Stereotactic radiosurgery, Blood samples
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
This expanded access study has being designed following a demand from the FDA, given the increase in the number of request for single patient INDs for lorlatinib
- Trial name
- NCT03178071
- Testing
- Lorlatinib
- Where
- 49 sites in United States
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC)
This study aims to assess both the role and cost-effectiveness of EBUS in preoperative Non small cell lung cancer staging. This controlled multicentric study will be conducted in 22 centers in France.
- Trial name
- EVIEPEB (NCT00960271)
- Testing
- EBUS
- Where
- France
- Volunteers
- 363 people
- Sponsor
- University Hospital, Rouen
Primary Malignant Neoplasm of Lung, Primary Malignant Neoplasm of Gastrointestinal Tract
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
To assess the feasibility of a creative writing intervention in an advanced cancer population. Given it is a relatively simple intervention delivered by a non-clinician, the investigators are interested in better understanding…
- Trial name
- NCT02575898
- Testing
- First Session, Second Session, Third through Sixth Sessions
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Lung Cancer (NSCLC), Radiation
GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung
Decreased respiratory function is a common side effect experienced by non-small cell lung cancer (NSCLC) patients who receive radiation therapy.
- Trial name
- INSPIRE (NCT07679607)
- Testing
- SOC Radiation Treatment Planning, INSPIRE Radiation Treatment Planning
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Maryland, Baltimore
Lung Cancer
The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer
Lung cancer is currently the leading cause of cancer-related mortality worldwide, and the dominant histopathology is non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT05541744)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Cannabis Use
Environment and Lung Cancer
Cannabis is the most consumed drug in the world and the French are the main consumers in Europe. The most recognized effects of cannabis on human health are of a neuro-psychic nature.
- Trial name
- ECP (NCT05119244)
- Testing
- blood and hair sampling
- Where
- 3 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed disease after first-line icotinib treatment.
- Trial name
- NCT03402464
- Testing
- Icotinib combined dihydroaremisinin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cardiovascular Diseases, Diabetes
Białystok PLUS - Polish Longitudinal University Study
The main goal of the study is to provide a unique multidimensional picture of the health of the population with simultaneous optimal standards of sampling, processing and storing of data and biomaterial that will allow…
- Conditions
- Cardiovascular Diseases, Diabetes, Neuro-Degenerative Disease, Obesity
- Trial name
- Bialystok+ (NCT03197363)
- Testing
- Discovering novel risk factors.
- Where
- Poland
- Volunteers
- 8,320 people
- Sponsor
- Medical University of Bialystok
Esophageal Cancer, Lung Cancer
Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas
Neo-adjuvant chemoradiotherapy (neo-CRT) is increasingly applied in the curative treatment of esophageal cancer, with the aim to downstage the tumor, to increase the rate of radical resections, and consequently to improve the…
- Trial name
- ABC (NCT02497664)
- Testing
- Active Breathing Control
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- University Medical Center Groningen
Non-small Cell Lung Cancer
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03.
- Trial name
- NCT01279798
- Testing
- Lucanix® (belagenpumatucel-L)
- Where
- United States
- Sponsor
- NovaRx Corporation
Severe Asthma
Swiss Severe Asthma Register
Asthma is one of the most common chronic diseases. Asthma is characterized by chronic airway inflammation and associated with airway hyperresponsiveness and reversible airflow obstruction.
- Trial name
- NCT03984253
- Where
- 10 sites in Switzerland
- Volunteers
- 600 people
- Sponsor
- Prof. Dr. Jörg Leuppi
Cancer, Heart Failure
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care
Virtual reality has been shown to be an effective way to treat pain and anxiety in various different settings. Palliative care is an area of medicine that often deals with patients suffering from pain and anxiety.
- Conditions
- Cancer, Heart Failure, Copd, ALS
- Trial name
- NCT04138095
- Testing
- Virtual Reality
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Riverview Health Centre
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Non-Small-Cell Lung Cancer
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC
This study aims to investigate the efficacy and safety of immuno-chemotherapy in combination of cryoablation as the first-line treatment of advanced NSCLC
- Trial name
- NCT06483009
- Testing
- Cryoablation
- Volunteers
- 20 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03624309
- Testing
- Anlotinib Plus Docetaxel, Docetaxel
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Hunan Cancer Hospital
Lung Cancer
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
The purpose of this study is studying icotinib following chemotherapy to see how well it works compared to chemotherapy in treating patients with resected stage IIA-IIIA NSCLC harboring EGFR mutation.
- Trial name
- ICTAN (NCT01996098)
- Testing
- 6-month Icotinib, 12-month icotinib
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Sun Yat-sen University
Lung Cancer, Head and Neck Cancer
Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy
In this study, the investigators obtain wearable disease based biomarkers from patients diagnosed with cancer and undergoing chemotherapy, and simultaneously measure patient self-reported adverse events through an app to evaluate…
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT05937477
- Testing
- Fitbit smartwatch
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Sehhoon Park
Non-small Cell Lung Cancer, Lung Cancer
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by…
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
- Trial name
- ALTA-1L (NCT02737501)
- Testing
- Brigatinib, Crizotinib
- Where
- 91 sites in United States, Australia and 17 more
- Volunteers
- 275 people
- Sponsor
- Ariad Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.